新型HBV血清学标志物的潜在临床价值  

Potential clinical value of new type of HBV serological markers ranking in the review column

作　　者：蒋贝[1] 吕菲南 郑晓雅 曹宇[1] 宓余强[1] Jiang Bei;Lyu Feinan;Zheng Xiaoya;Cao Yu;Mi Yuqiang(Tianjin Second People’s Hospital,Tianjin Institute of Hepatology,Tianjin 300192,China;Graduate School,Tianjin Medical University,Tianjin 300070,China)

机构地区：[1]天津市第二人民医院天津市肝病医学研究所,300192 [2]天津医科大学研究生院,300070

出　　处：《中华肝脏病杂志》2020年第8期711-714,共4页Chinese Journal of Hepatology

基　　金：天津市自然科学基金(18JCQNJC11800);中国肝炎防治基金会-天晴肝病研究基金(TQGB20190021)。

摘　　要：在我国,慢性乙型肝炎(CHB)及其所导致的纤维化、肝硬化和肝细胞癌仍是严重影响人群健康的重大疾病。很多患者经治疗虽然检测不到血清HBV DNA,但也会出现肝脏疾病的进展,因此,应该寻找除HBV DNA、HBsAg定量之外的新型血清学标志物,有利于CHB抗病毒药物及方式的选择、疗效监测随访、疗效预测以及预测停药后病毒学反弹风险等。现重点阐述HBV核心相关抗原、HBV RNA、抗-HBc这三种新型有望应用于临床实践的血清学标志物。Liver fibrosis,liver cirrhosis and hepatocellular carcinoma caused by chronic hepatitis B are still the main diseases that seriously affect the health of Chinese population.Notably,even if serum HBV-DNA cannot be detected after treatment,many patients will still develop liver disease.Therefore,in addition to the quantitative analysis of HBV-DNA and HBsAg,other new serological markers should be sought to facilitate the selection of CHB antiviral drugs and methods,monitoring efficacy and follow-up,efficacy prediction,and the risks of viral rebound after drug withdrawal.This article focuses on three new serological markers,namely HBcrAg,HBV-RNA and anti-HBc,with a view to applying them in clinical practice.

关 键 词：肝炎 乙型 慢性 肝炎病毒 乙型 标志物 

分 类 号：R512.62[医药卫生—内科学]